• Mechanism of Action
• Binds to and inhibits fast sodium channels responsible for rapid depolarisation during phase 0 of the cardiomyocyte action potential.
• • Pharmacology
  • Acts on cardiomyocytes, with no action on pacemaker cells whose phase 0 is mediated by calcium influx. Moderate sodium channel blockade, but increases the absolute refractory period (ARP).

Clinical Use

• • Indications
  • Cardioversion of atrial fibrillation / flutter
  • Acute ventricular tachycardia
• • Adverse Effects
  • Anticholinergic - dry mouth, blurred vision, constipation, urinary retention
  • Nausea / vomiting / diarrhoea
  • Headache
  • Fatigue